CLC Number:
| [1] Hornick JL, Fletcher CD. PEComa: what do we know so far?[J]. Histopathology, 2006, 48(1): 75-82. [2] Kallen ME, Hornick JL. The 2020 WHO classification: whats new in soft tissue tumor pathology?[J]. Am J Surg Pathol, 2021, 45(1): e1-e23. [3] Fadare O. Perivascular epithelioid cell tumor(PEComa)of the uterus: an outcome-based clinicopathologic analysis of 41 reported cases[J]. Adv Anat Pathol, 2008, 15(2): 63-75. [4] Kenerson H, Folpe AL, Takayama TK, et al. Activation of the mTOR pathway in sporadic angiomyolipomas and other perivascular epithelioid cell neoplasms[J]. Hum Pathol, 2007, 38(9): 1361-1371. [5] Kovac O, Babal P, Kajo K, et al. Perivascular epithelioid cell tumor(PEComa)of the uterine cervix: a case report of a 43-yr-old woman with abnormal utering treated with hysterectomy[J]. Int J Gynecol Pathol, 2018, 37(5): 492-496. [6] Bennett JA, Braga AC, Pinto A, et al. Uterine PEComas: a morphologic, immunohistochemical, and molecular analysis of 32 tumors[J]. Am J Surg Pathol, 2018, 42(10): 1370-1383. [7] Folpe AL, Mentzel T, Lehr HA, et al. Perivascular epithelioid cell neoplasms of soft tissue and gynecologic origin: a clinicopathologic study of 26 cases and review of the literature[J]. Am J Surg Pathol, 2005, 29(12): 1558-1575. [8] Bennett JA, Ordulu Z, Pinto A, et al. Uterine PEComas: correlation between melanocytic marker expression and TSC alterations/TFE3 fusions[J]. Mod Pathol, 2022, 35(4): 515-523. [9] Rao Q, Cheng L, Xia QY, et al. Cathepsin K expression in a wide spectrum of perivascular epithelioid cell neoplasms(PEComas): a clinicopathological study emphasizing extrarenal PEComas[J]. Histopathology, 2013, 62(4): 642-650. [10] Valencia-Guerrero A, Pinto A, Anderson WJ, et al. PNL2: a useful adjunct biomarker to HMB45 in the diagnosis of uterine perivascular epithelioid cell tumor(PEComa)[J]. Int J Gynecol Pathol, 2020, 39(6): 529-536. [11] Stone JL, Batty T, Nicklin J. Cervical perivascular epithelioid cell tumour(PEComa)of the uterine cervix: cytological findings in a cervical smear[J]. Cytopathology, 2013, 24(4): 272-273. [12] Tajima S, Koda K. Perivascular epithelioid cell tumor of the uterine cervix identified on a conventional cervical smear[J]. Diagn Cytopathol, 2015, 43(12): 1011-1016. [13] Zhang C, Pan F, Qiao J, et al. Perivascular epithelioid cell tumor of the cervix with malignant potential[J]. Int J Gynaecol Obstet, 2013, 123(1): 72-73. [14] Sanfilippo R, Jones RL, Blay JY, et al. Role of chemotherapy, VEGFR inhibitors, and mTOR inhibitors in advanced perivascular epithelioid cell tumors(PEComas)[J]. Clin Cancer Res, 2019, 25(17): 5295-5300. [15] Le P, Garg A, Brandao G, et al. Hormonal manipulation with letrozole in the treatment of metastatic malignant pecoma[J]. Curr Oncol, 2014, 21(3): e518-e520. [16] Chiang S, Vasudevaraja V, Serrano J, et al. TSC2-mutant uterine sarcomas with JAZF1-SUZ12 fusions demonstrate hybrid features of endometrial stromal sarcoma and PEComa and are responsive to mTOR inhibition[J]. Mod Pathol, 2022, 35(1): 117-127. [17] Wagner AJ, Ravi V, Riedel RF, et al. nab-sirolimus for patients with malignant perivascular epithelioid cell tumors[J]. J Clin Oncol, 2021, 39(33): 3660-3670. [18] Gu X, Yu JJ, Ilter D, et al. Integration of mTOR and estrogen-ERK2 signaling in lymphangioleiomyomatosis pathogenesis[J]. Proc Natl Acad Sci U S A, 2013, 110(37): 14960-14965. [19] Sanfilippo R, Fabbroni C, Fucà G, et al. Addition of antiestrogen treatment in patients with malignant PEComa progressing to mTOR inhibitors[J]. Clin Cancer Res, 2020, 26(20): 5534-5538. [20] McBride A, Garcia AJ, Sanders LJ, et al. Sustained response to pembrolizumab in recurrent perivascular epithelioid cell tumor with elevated expression of programmed death ligand: a case report[J]. J Med Case Rep, 2021, 15(1): 400. [21] 陈筱莉,蹇顺海,杨慧敏,等.伴TFE3基因易位的子宫颈PEComa 1例并文献复习[J].重庆医学, 2020, 49(21): 3569-3573. CHEN Xiaoli, JIAN Shunhai, YANG Huimin, et al. Cervical perivascular epithelioid cell tumor with TFE3 gene translocation: a case report and literature review [J]. Chongqing Medicine, 2020, 49(21): 3569-3573. |
| [1] | . [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(11): 93-94. |
| [2] | LU Zhenzhen, YAN Lei, ZHANG Hui, ZHANG Xiaohui, ZHAO Xingbo. Effects of TGF β-1 on the activation of endometrial stromal cells in tumor microenvironment [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(9): 37-40. |
| [3] | ZHANG Xiaohui, YAN Lei, QI Shasha, LU Zhenzhen, LI Mingjiang, ZHAO Xingbo. Occurrence of epithelia-mesenchymal transition in endometrial adenocarci-noma and the roles of miR200a/ZEB1 signaling pathway in this process [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(7): 48-52. |
| [4] |
LIU Jian-meng， CUI Bao-xia， YIN Ting， ZHANG Ai-rong.
Expression and significance of pigment epithelium-derived factor in cervix squamous cell carcinoma [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(5): 103-106. |
| [5] | SU Shan1, KAN Yanyan1， TIAN Yongjie2. Expressions and significances of sFRP-1 and Wnt-1 in cervical carcinoma and precancerous lesions [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2010, 48(1): 97-101. |
| [6] | GUO Sunwei, LIU Xishi. Cracking the enigma of pathogenesis and pathophysiology of adenomyosis [J]. Journal of Shandong University (Health Sciences), 2022, 60(7): 6-19. |
| [7] | YU Mei, YANG Jiaxin, CAO Dongyan, WANG Yao, SHEN Keng. Diagnosis and management in patients with recurrent stage I endometrial cancer after primary fertility-preserving treatment [J]. Journal of Shandong University (Health Sciences), 2018, 56(5): 23-29. |
| [8] | LENG Jinhua, SHI Jinghua. Clinical manifestations of adenomyosis [J]. Journal of Shandong University (Health Sciences), 2022, 60(7): 1-5. |
| [9] | ZHANG Xinmei, XU Ping. Surgical treatment strategies of adenomyosis [J]. Journal of Shandong University (Health Sciences), 2022, 60(7): 26-31. |
| [10] | . [J]. Journal of Shandong University (Health Sciences), 2019, 57(1): 118-120. |
| [11] | YI Xiaofang, HUANG Jihua. Patient education and proper management of adenomyosis [J]. Journal of Shandong University (Health Sciences), 2022, 60(7): 32-35. |
| [12] | AILI Aixingzi, GUO Zhengyu, ZHANG Xiaofei. Latest research advances of high intensity focused ultrasound treatment for adenomyosis [J]. Journal of Shandong University (Health Sciences), 2022, 60(7): 36-42. |
| [13] | TAO Guowei, WANG Fang, DONG Xiangyi, XU Yaxuan, ZHAO Linli, HU Beibei. Diagnosis of adenomyosis using ultrasound and magnetic resonance imaging [J]. Journal of Shandong University (Health Sciences), 2022, 60(7): 56-65. |
| [14] | PENG Chao, ZHOU Yingfang. Progress on the medical treatment of adenomyosis [J]. Journal of Shandong University (Health Sciences), 2022, 60(7): 20-25. |
| [15] | . [J]. Journal of Shandong University (Health Sciences), 2019, 57(12): 118-120. |
|
